---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-032514"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T14:51:24.284737+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Syndax appoints Steven Closter as CCO as Steve Sabus resigns; expects two product launches in 2024

## Summary
- Steve Sabus voluntarily resigned as CCO on March 15, 2024 due to personal reasons.
- Steven Closter appointed CCO effective March 18; leads commercial strategy for anticipated launches of revumenib and axatilimab.
- Closter received base salary $460K, 45% target bonus, option for 150K shares, PRSU of 25K units, and sign-on RSU of 9K units.
- Closter brings over 30 years biopharma commercial experience, previously VP at Sunovion/Sumitomo Pharma America and Forest Labs/Allergan.
- Company reaffirms on track for two first- and best-in-class product launches in 2024.

## SEC filing metadata
- accession: 0000950170-24-032514
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017024032514/0000950170-24-032514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017024032514/sndx-20240315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-032514
- JSON: https://secwatch.observer/filing/0000950170-24-032514.json
- Plain text: https://secwatch.observer/filing/0000950170-24-032514.txt

## Key facts
- Executive change
  Steven Closter was appointed as Chief Commercial Officer at Syndax Pharmaceuticals Inc.
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: On March 18, 2024, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steven Closter will join the Company as Chief Commercial Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017024032514/0000950170-24-032514-index.htm
- Executive change
  Steve Sabus resigned as Chief Commercial Officer at Syndax Pharmaceuticals Inc.
  - Action: resigned
  - Role: Chief Commercial Officer
  source text: On March 15, 2024, Steve Sabus, the previous Chief Commercial Officer of the Company, notified the Company of his voluntary resignation from his position due to personal reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017024032514/0000950170-24-032514-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.